Table 3.

Summary of meta-analyses of RCTs for ω3 PUFA treatment of Adults with NAFLD¹.

	Clinical Trials	Patients	ω3 PUFA Dose, g/d	Duration (Months)	Meta-Analysis			Outcomes
Musso, et al (2010)					IV, Random	95% CI^L	95% CI^H	Favors
Plasma ALT	3	182	2 to 4	2 to 6	−32.24	−39.99	−24.48	ω3-PUFA
Parker, et al, (2012)					Hedge’s G	95% CI^L	95% CI^H	Favors
Liver Fat	7	331	0.83 to 5	2 to 12	−0.965	−1.348	−0.582	ω3-PUFA
Plasma ALT					−0.563	−1.153	−0.031	ω3-PUFA
Plasma AST					−0.971	−1.815	−0.127	ω3-PUFA
Lu, et al (2016)					M-H Random	95% CI^L	95% CI^H	Favors
Liver Fat	5	268	0.83 to 5	12	3.6	1.31	9.98	ω3-PUFA
					IV Random	95% CI^L	95% CI^H	Favors
Plasma ALT	8	530	0.83 to 4	2 to 18	−4.97	−11.14	1.2	NE
Plasma AST	7	496	0.83 to 4	2 to 18	−2.01	−8.72	4.7	NE
HDL-C	7	472	0.83 to 9	2 to 18	5.11	−0.03	11	ω3-PUFA
LDL-C	6	433	0.83 to 9	2 to 18	1.28	−4.06	6.63	NE
Total Cholesterol	7	474	0.83 to 4	2 to 18	−3.65	−10.4	3.09	NE
Triglycerides	9	561	0.83 to 4	2 to 18	−35.55	−53.9	−17.19	ω3-PUFA
He, et al (2016)					IV Fixed	95% CI^L	95% CI^H	Favors
Plasma ALT	6	396	0.83 to 6.4	6 to 18	−7.61	−12.38	−2.39	ω3-PUFA
Plasma γGT	3	181	0.83 to 2.0	6 to 12	−8.28	−18.38	1.83	ω3-PUFA
Triglycerides	7	442	0.83 to 6.4	6 to 18	−43.96	−51.21	−36.71	ω3-PUFA
					IV Random	95% CI^L	95% CI^H	Favors
Plasma AST	5	362	0.83 to 6.4	6 to 18	−6.89	−17.71	3.92	ω3-PUFA
Plasma Cholesterol	6	396	0.83 to 6.4	6 to 18	−13.41	−21.44	−5.38	ω3-PUFA
LDL-C	6	360	0.83 to 6.4	6 to 18	−7.31	−14.26	0	ω3-PUFA
HDL-C	6	398	0.83 to 6.4	6 to 18	6.97	2.05	11.9	ω3-PUFA

Abbreviations: CI^L, confidence interval-low value; CI^H, confidence interval-high value; NE, no effect; ALT, alanine aminotransferase, AST, aspartate, aminotransferase, γGT, γ-glutamyl aminotransferase.